Recombinant human anti-Lewis Y antibodies

• US 6,310,185 B1
• Filed: 03/08/1994
• Issued: 10/30/2001
• Est. Priority Date: 03/08/1994
• Status: Expired due to Term

• Current Assignee: Memorial Sloan-Kettering Cancer Center
• Original Assignee: Memorial Sloan-Kettering Cancer Center
• Inventors: Wallace, Thomas P., Old, Lloyd J., Carr, Francis Joseph, Stockert, Elisabeth, Garin-Chesa, Pilar, Welt, Sydney, Armour, Kathryn Lesley, Kitamura, Kunio
• Primary Examiner(s): Feisee, Lila
• Assistant Examiner(s): UNGAR, SUSAN NMN
• Application Number:
  US08/207,861
• Time in Patent Office: 2,793 Days
• Field of Search: 435/240.27, 530/387.3, 530/388.8, 424/141.1, 424/155.1
• US Class Current: 530/388.8
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/34 against blood group antigens
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by murine atibodies specific for the Lewis Y antigen. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumour types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumours. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

Claims

1. A humanized antibody that specifically binds to the Lewis Y antigen, comprising a humanized variable region wherein a heavy chain variable region is selected from the group consisting of 3S193HuVH (SEQ ID NO:

22), 3S 193 HuVHT (SEQ ID NO;

     23) in which the framework region of the heavy chain variable region comprises an amino acid substitution of threonine at position 24, 3S193 HuVHA (SEQ ID NO;

     24) in which the framework region of the heavy chain variable region comprises an amino acid substitution of alanine at position 74, 3S193 HuVHAS (SEQ ID NO;

     25) in which the framework region of the heavy chain variable region comprises an amino acid substitution of serine at position 76 and 3S193 HuVHASY (SEQ ID NO;

     26) in which the framework region of the heavy chain variable region comprises an amino acid substitution of tyrosine at position 79, and a light chain variable region is selected from the group consisting of 3S193 HuVK (SEQ ID NO;

     28) and 3S193 HuVKF (SEQ ID NO;

     33) in which the framework region of the light chain variable region comprises an amino acid substitution of phenylalanine at position 71.

2. An antibody according to claim 1, wherein the heavy chain variable region and the light chain variable region are from murine antibody 3S193.

3. A labeled immunoglobulin molecule comprising an immunoglobulin molecule according to claim 2 and a detectable label.

4. An antibody according to claim 2, wherein the framework region of the heavy chain variable region is derived from an KOL framework region.

5. An antibody according to claim 2, wherein the framework region of the light chain variable region is derived from a REI framework region.

6. An antibody according to claim 5, wherein the framework region of the heavy chain variable region is derived from a KOL framework region.